Further to the TSX Venture Exchange bulletin dated Nov. 9, 2023, the exchange has received confirmation of the company's effective date of trading on a postconsolidated basis.

Pursuant to a special resolution passed by shareholders on Oct. 27, 2023, the company has consolidated its capital on a one-new-for-nine-old basis. The name of the company has not been changed.

Effective at the opening, Tuesday, Nov. 14, 2023, the common shares of the company will commence trading on the TSX Venture Exchange on a consolidated basis. The company is classified as a pharmaceutical company.

Postconsolidation

Capitalization:  unlimited shares with no par value, of which 1,998,854 shares are issued and outstanding

Escrow:  nil shares subject to escrow

Transfer agent:  TSX Trust Company

Trading symbol:  XRTX (unchanged)

Cusip No.:  98420Q 30 6 (new)